Q1 2026 Earnings Detail Revenue & EPS Decline, Strong Cash Maintained

summarizeSummary

Utah Medical Products reported Q1 2026 revenue and EPS declines of 10.2% and 11.0% respectively, consistent with prior announcements. The company maintained a strong cash position and improved gross margins, despite increased operating expenses and reduced share repurchases.

check_boxKey Events

• Q1 2026 Financial Performance

  Net sales declined 10.2% to $8.72 million, and diluted EPS dropped 11.0% to $0.82 compared to Q1 2025. These results were previously announced in an 8-K filing on April 23, 2026.

• Gross Margin Improvement

  Gross profit margin increased to 60.6% in Q1 2026 from 57.0% in Q1 2025, driven by a more favorable product mix despite lower overall sales.

• Operating Income Decline

  Operating income decreased by 18.7% to $2.57 million, impacted by a $125,000 increase in litigation expenses and higher employee healthcare costs.

• Strong Cash Position Maintained

  Cash and investments increased by $1.65 million during Q1 2026, reaching $87.41 million, demonstrating a robust balance sheet with no debt.

auto_awesomeAnalysis

Utah Medical Products reported a 10.2% decline in Q1 2026 revenue and an 11.0% drop in diluted EPS compared to Q1 2025. These results were consistent with previously reported preliminary figures. The revenue decline was primarily attributed to the expected loss of a major China distributor and an OEM customer. Despite lower sales, the company improved its gross profit margin to 60.6% from 57.0% in the prior year, partly due to a more favorable product mix and an inventory valuation adjustment. Operating income, however, decreased by 18.7% due to higher litigation expenses and increased employee healthcare costs. A positive note for future quarters is the completion of the Femcare IIA amortization in Q1 2026, which will result in zero amortization expense going forward. The company maintains a strong balance sheet with cash and investments increasing to $87.4 million, and continues its long-term share repurchase program, though Q1 2026 repurchases were significantly lower than Q1 2025.